Dostarlimab around surgery for certain untreated colon cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have untreated, confirmed colon adenocarcinoma (colon cancer)
- Your cancer can be fully removed with surgery and is either T4N0 or stage III (no spread to distant organs)
- Your scans can be measured or followed on imaging (radiologically evaluable disease)
- Your tumor test shows either dMMR or MSI-H (specific “DNA repair” or “microsatellite” results)
- You have NOT already had treatment for this colon cancer (no chemo, immunotherapy, targeted therapy, radiation, or surgery)
- You do NOT have distant metastatic disease (cancer spread to other organs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (CAPEOX) is more effective than chemotherapy alone for people with a specific type of colon cancer (MMRp/MSS) that has not spread. It is given before surgery to shrink the tumor.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests different lengths of treatment with the drug dostarlimab for people with a specific type of rectal cancer that has a high number of genetic mutations. The goal is to find the best duration of treatment to improve outcomes.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
Hear when a new Colonic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.